Further, using clinical tissue specimens of gastric cancers, we showed that METTL9 elevation is characteristic in patients with peritoneal dissemination, indicating that METTL9 can be a candidate of molecular targets for inhibiting peritoneal dissemination. The gene discussed is METTL9; the disease is gastric cancer.